News and Trends 8 Oct 2019 UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut. The partners will develop vaccines against three undisclosed conditions. As well as an undisclosed upfront fee for each condition, 4D Pharma will be eligible to receive up to €316.5M ($347.5M) in developmental milestones. […] October 8, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2019 Microbiome Food Supplement Improves Metabolic Syndrome in Overweight People A food supplement made from bacteria, developed by a Belgian research group, has improved symptoms of the metabolic syndrome including insulin resistance and high blood cholesterol levels in overweight volunteers at risk of heart disease and type 2 diabetes. The metabolic syndrome is a collection of conditions including high blood cholesterol, insulin resistance and high […] July 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2019 Will US Fecal Transplant Death Impact European Biotech? The death of a US patient from complications after a fecal transplant last week could have a major impact on microbiome research in Europe. The microbiome is a field with big potential for treating disease by targeting imbalances in the patient’s gut flora, such as by giving patients the stool bacteria of a healthy person […] June 21, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2019 Highlights from European Biotech at ASCO 2019 European biotech companies gathered in Chicago, USA, to share the latest advances in cancer research at the biggest cancer conference of the year, ASCO 2019. This year’s conference has drawn fewer big blockbuster headlines than other years, but there was plenty to see nonetheless. There were results from many different clinical trials by big pharma […] June 5, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2019 Microbiome Companies Unite to Push for EU Regulation Reform European microbiome biotechs have launched a collaboration to streamline the EU’s regulatory pathways for microbiome-based treatments, which have the potential to treat inflammatory disease and bacterial infection. The companies will propose EU regulatory changes that make it easier to commercialize treatments based on targeting a patient’s microbiome bacteria. Microbiome-based treatments form a young field in […] May 22, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 15 May 2019 The Missing Piece in the Microbiome Field Over the last decade, the biotech industry has built a lot of hype around the emerging field of microbiome research. Its potential to treat all sorts of diseases has captured the imagination of scientists and the number of early-stage studies is growing massively day by day. These studies have found correlation between the human microbiome […] May 15, 2019 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 6 May 2019 2019 Will Be a “Year of Realism” for Biotech Investments Biotech investors regularly jump on new crazes, including the microbiome and CRISPR-Cas9 gene editing. At BIO-Europe Spring 2019, Regina Hodits, Managing Partner at German VC firm Wellington Partners Life Sciences, spoke to us about the firm’s realistic approach to biotech investment. Biotechnology is an industry with high risks and high rewards. Before a medical biotech […] May 6, 2019 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 19 Apr 2019 This Biotech Fertilizes Crops with Little Microbe Capsules We’re zooming over to France this week. The biotech Kapsera makes capsules of microbes that present a cheaper and more sustainable alternative to traditional fertilizers and insecticides. Mission: To develop biodegradable capsules containing microbes. These treatments could control pests and fertilize crops in a more sustainable way than chemical treatments. Agriculture is facing tough challenges […] April 19, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2019 Joint Venture First to Offer Seamless Manufacturing of Microbiome Therapies Lonza, a Swiss pharma supplier, and Chr. Hansen, a Danish supplier of bacterial products, are teaming up to enter the promising microbiome space. Together, the two companies will invest €90M in the creation of the first company that will offer a full supply chain to produce treatments made of live bacteria. Their 50/50 joint venture […] April 3, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2019 Danish Biotech to Develop CRISPR-Based Microbiome Treatments SNIPR Biome has raised €43M in Series A funds to develop treatments that precisely target ‘bad’ bacteria using CRISPR gene editing, while keeping the rest of the patient’s microbiome intact. Founded with €2.6M seed investment from the Lundbeck Foundation in 2017, SNIPR Biome was the first exploratory investment for the Danish organisation’s Emerge fund, which […] March 11, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 5 Mar 2019 Seventure Continues Microbiome Investment Success with Second Fund After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […] March 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2019 Microbiome Biotech Will Use Series B to Bring Treatments to Clinic The Israeli biotech BiomX has raised €28M ($32M) to advance its treatments for acne and inflammatory bowel disease to the clinical stage. Investor interest is continuing in treatments based on the microbiome, which have the potential to treat a variety of conditions such as chronic inflammatory diseases, and even some forms of cancer. BiomX’s approach […] February 21, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email